WATCHMAN FLXTM Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLXTM Pro Left Atrial Appendage Closu
Boston Scientific Corp · Decision date Apr 23, 2026
What did the FDA decide?
FDA records P130013/S085 as a supplement to PMA P130013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 23, 2026.
FDA approval order statement
to add an alternate broken strut inspection system for the WATCHMAN FLX Left Atrial Appendage (LAA) Closure Device with Delivery System and WATCHMAN FLX Pro LAA Closure Device with Delivery System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Apr 23, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130013/S085
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NGV
- Decision code
- OK30
- Decision date
- Apr 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, appendage closure, left atrial.
- Applicant
- Boston Scientific Corp
- Product code
- NGV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130013/S077 · Related supplement
WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY
P130013/S081 · Related supplement
WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLX Left Atrial Appendage Closure D
P130013/S080 · Related supplement
WATCHMAN FLX Left Atrial Appendage (LAA) Closure Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage (
P130013/S078 · Related supplement
WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System
P130013/S079 · Related supplement
WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System
P130013/S082 · Related supplement
WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Cl
P130013/S083 · Related supplement
WATCHMAN FLX Pro Left Atrial Appendage Closure Device with Delivery System
P130013/S076 · Related supplement
WATCHMAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE TECHNOLOGY
P130013/S085 received
Application receipt date recorded by FDA.
P130013/S085 · FDA decision
30-Day Notice
P130013/S084 · Related supplement
WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Closure
P130013/S086 · Related supplement
WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Closure
P130013/S089 · Related supplement
WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System WATCHMAN FLX Pro Left Atrial Appendage Closure D
P130013/S090 · Related supplement
WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device with Delivery System; WATCHMAN FLX Pro Left Atrial Appendage Cl
Timeline entries are records held by MedtechLedger for P130013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA supplement | Sep 4, 2025 | FDA | |
| Boston Scientific Corp | PMA supplement | Nov 6, 2025 | FDA | |
| Boston Scientific Corp | PMA supplement | Dec 12, 2025 | FDA | |
| Boston Scientific Corp | PMA supplement | Dec 15, 2025 | FDA | |
| Boston Scientific Corp | PMA supplement | Dec 15, 2025 | FDA | |
| Boston Scientific Corp | PMA supplement | Dec 18, 2025 | FDA | |
| Boston Scientific Corp | PMA supplement | Feb 12, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Mar 25, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | May 18, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Jul 21, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Aug 21, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Aug 28, 2026 | FDA |
Explore the linked device profile
Other records with product code NGV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S021 | ABBOTT MEDICAL | PMA supplement | Aug 28, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | May 28, 2026 | FDA | |
Amplatzer Amulet Left Atrial Appendage OccluderP200049/S017 | ABBOTT MEDICAL | PMA supplement | Mar 19, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Feb 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- One Scimed Pl., Maple Grove, MN, 55311
Sources and methodology
- Original FDA record: P130013/S085
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





